Information regarding the exercise period of warrants of series TO 1 in Genetic Analysis
Oslo, Norway, November 2, 2022 – On November 2, 2022, the exercise period for the warrants of series TO 1 issued in connection with Genetic Analysis AS’s (“GA” or the…
Interim report January – September 2022
Oslo, Norway, November 1, 2022 – Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for the period January 1 – September 30, 2022. The interim report…
Genetic Analysis appoints Sedermera Corporate Finance AB to act as a liquidity provider for the Company´s share
Oslo, Norway, September 1, 2022 – Genetic Analysis AS (“GA” or “the Company”) has appointed Sedermera Corporate Finance as the Company’s liquidity provider. The assignment will commence on the 5…
Interim report January – June 2022
Oslo, Norway, August 18, 2022 – Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for the period January 1 – June 30, 2022. The interim report…
Genetic Analysis and Servatus enter Strategic Collaboration Agreement to develop new microbiome diagnostic and therapeutic solutions
The Strategic Collaboration Agreement will enable both parties to utilise extensive knowledge sharing for microbiome diagnostics and biotherapeutics development Genetic Analysis is a Norway-based diagnostic company and a pioneer in…
Genetic Analysis AS: Mandatory notification of trade – Primary Insider
OSLO, NORWAY – 20 May 2022: Genetic Analysis AS (“GA” or “the Company”) announce that a member of the management has bought GEAN-shares. Ronny Hermansen, CEO in Genetic Analysis AS,…
Genetic Analysis AS and Omnigene Medical Technologies Ltd. enter a distribution agreement to launch GA-map® in the United Arabic Emirates (UAE) market
OSLO, NORWAY – May 19, 2022: Molecular diagnostics specialist, Genetic Analysis AS (“GA”) hereby announces that GA has entered a distribution and technology transfer agreement with Omnigene Medical Technologies Ltd….
Interim report January – March 2022
Oslo, Norway, May 13, 2022 – Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for the period January 1 – March 31, 2022. The interim report…
Minutes from the Annual General Meeting 2022 in Genetic Analysis AS
Oslo, Norway, April 29, 2022 – Genetic Analysis AS (the “Company”, Ticker: GEAN) held its Annual General Meeting on April 28 at 15:00 hours (CET) on the Company’s premises in…
Publication of Genetic Analysis’ 2021 Annual Report
(Oslo, April 21, 2022) Genetic Analysis AS (“GA” or “the Company”) hereby publishes the Annual Report for the financial year of 2021. The Annual Report is available as an attached…
Notice of Annual General Meeting 2022
Oslo, Norway, April 21, 2022 – Notice is hereby served that the Annual General Meeting of Genetic Analysis AS (the “Company”) will be held on Thursday 28 April at 15:00…
Genetic Analysis strengthens its management team by hiring a Head of Operations
OSLO, NORWAY – 4 March 2022: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces today that the Company has strengthened its management team by hiring Mr. Lars…
Year-End Report October – December 2021
(Oslo, 18 February 2022) Genetic Analysis AS (“GA” or “the Company”) hereby publishes the year-end report for the period 1 October – December 31, 2021. The year-end report is available…
IMD – Institut für Medizinische Diagnostik launches the GA-map® Microbiome Test in Germany
OSLO, NORWAY/BERLIN, GERMANY – 15 February 2022: Microbiome DX company Genetic Analysis AS (“GA”) and Institut für Medizinische Diagnostik (“IMD”), a part of the Medicover Group, announces today that IMD…
The Microbiome Test from Genetic Analysis AS launched on a new technology platform, GA-map® Dysbiosis Test kit now commercially available on the Luminex MAGPIX® system
OSLO, NORWAY – 1. February 2022: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces that the Company has successfully completed the development and CE-marking of the GA-map®…